There has been a significant decrease in morbidity and mortality associated with acute coronary syndrome over the past few decades. The mortality from acute coronary syndrome that was somewhere between 30-40% in 1960s has significantly reduced to 6-7% in 2010. This marked improvement is primarily due to the advancement in drug developments, coronary care units, and the clinical trials done in the area. Despite these advancements diabetes put an added challenge in these groups of patients and is associated with poor prognosis. Additionally, hyperglycemia with or without documented history of diabetes acts as a predictor for mortality in the patients with acute coronary syndrome. However, there has been a lack of consensus regarding the<unk>  levels at which the treatment should be initiated, target<unk>  level, type of treatment (insulin), mode of insulin administration. Thus, large randomized clinical trials addressing these issues are warranted in this area.
ST elevation myocardial infarction glucose control
ST elevation myocardial infarction aspirin therapy
ST elevation myocardial infarction calcium channel blocker therapy
ST elevation myocardial infarction analgesic therapy
ST elevation myocardial infarction pre-hospital care
ST elevation myocardial infarction anticoagulant and antithrombotic therapy
ST elevation myocardial infarction fibrinolytic therapy
Respiratory failure electrocardiogram